Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Karin Nachbaur"'
Autor:
Wolfgang Vogel, Ivo Graziadei, Karin Nachbaur, Michael Joannidis, Johann Pratschke, Armin Finkenstedt, Heinz Zoller
Publikováno v:
Liver Transplantation. 19:879-886
Acute-on-chronic liver failure (ACLF) is characterized by high short-term mortality. Liver transplantation (LT) is a potential therapy for patients who do not improve with supportive measures, but the efficacy of LT has not been shown. The aim of thi
Autor:
Anna Schloegl, Gregor Mikuz, Raimund Margreiter, Heinz Zoller, Walter Mark, Ivo Graziadei, Karin Nachbaur, Johann Pratschke, Karl-Peter Pfeiffer, Wolfgang Vogel
Publikováno v:
Liver Transplantation. 18:671-679
There have been few detailed studies of viral kinetics after liver transplantation (LT), and conflicting data have been reported on viral loads and the severity of recurrent hepatitis C virus (HCV) disease. This long-term study aimed to examine (1) t
Autor:
Alfred Koenigsrainer, Wolfgang Vogel, Ivo Graziadei, Raimund Margreiter, Robert Koch, Hubert Schwaighofer, Karin Nachbaur
Publikováno v:
Liver Transplantation. 12:718-725
Biliary strictures are one of the most common complications following liver transplantation (LT), with an incidence of 5.8-34%. Endoscopic techniques have been successfully used to treat biliary complications; however, the long-term efficacy and safe
Autor:
Sabine Pankuweit, Patrycja Jonetzko, Wolfgang Vogel, Ivo Graziadei, Ralf H. Zwick, Karin Nachbaur, Gerhard Poelzl, Otmar Pachinger
Publikováno v:
Liver Transplantation. 11:463-466
Acute myocarditis may result in severe hemodynamic compromise with fatal outcome. Furthermore, recent studies suggest myocarditis as a major cause of sudden unexpected death. A variety of cardiotropic viral, rickettsial, and bacterial infectious agen
Autor:
Karin Nachbaur, Harald Brunner, Wolfgang Jessner, Peter Ferenci, Rudolf E. Stauber, Petra Steindl-Munda, Martha Rosenbeiger, Harald Hofer, Christian Datz, Alfred Gangl, Wolfgang Vogel, Michael Gschwantler, Franz Hackl
Publikováno v:
Liver International. 23:269-275
Background/aims: Initial high-dose interferon-α induction therapy in combination with ribavirin improves sustained response rates in treatment-naive patients. This prospective, randomized, controlled study tested whether non-responders or relapsers
Autor:
Alfred Koenigsrainer, Wolfgang Vogel, Ivo Graziadei, Werner Jaschke, Raimund Margreiter, Heiko Sandmueller, Peter Waldenberger, Karin Nachbaur
Publikováno v:
Liver Transplantation. 9:557-563
Orthotopic liver transplantation (OLT) has been considered the best treatment option for patients with hepatocellular carcinoma (HCC). Because of a steadily increasing waiting time, a noteworthy proportion of patients are excluded from OLT because of
Autor:
Otto Dietze, Manfred Herold, Herbert Braunsteiner, Wolfgang Vogel, Josef Thaler, Karin Nachbaur
Publikováno v:
European Journal of Haematology. 49:221-223
Autor:
Franz Allerberger, Karin Nachbaur, Rudolf Kirchmair, Isolde Bangerl, Josef R. Patsch, C. Egger, Wolfgang Vogel
Publikováno v:
Digestive Diseases and Sciences. 43:1129-1132
Autor:
Alfred Königsrainer, Bernhard Riedmann, Wolfgang Vogel, Karin Nachbaur, Heinrich Pernthaler, Raimund Margreiter
Publikováno v:
Transplant International. 8:492-495
A 54-year-old male presented with acute rejection and life-threatening gastrointestinal bleeding 2 months following orthotopic liver transplantation. Since no bleeding was identified in the entire gastrointestinal (GI) tract, hematobilia was first su
Autor:
Wilhelm Oberaigner, Walter Mark, Wolfgang Vogel, Ivo Graziadei, Raimund Margreiter, Karin Nachbaur, Armin Finkenstedt, Wolfgang Hilbe
Publikováno v:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 9(10)
The aim of our study was to examine whether an extensive surveillance protocol will promote early diagnosis and improved survival in patients with de novo cancer following liver transplantation (LT). Of 779 consecutive LT recipients, 96 (12.3%) devel